Posted: DEC 05, 2006

CSMG Technologies Receives Canadian Patent for Tissue Welding/Bonding Technology

Anticipates To File For U.S. and European Marketing Approval Early 2007

Corpus Christi, TX, December 05, 2006 -- CSMG Technologies, Inc., (OTC Bulletin Board: CTUM - News), a technology management company focused on commercializing human live tissue bonding devices, today announced it has received a Canadian patent for its platform tissue welding/bonding technology bringing to six the number of patents issued worldwide thus far.

CSMG President and CEO Donald S. Robbins said, "Prior to receiving the patent in Canada, three U.S. patents, an Australian patent and a European Union patent have been issued. We believe that our patent portfolio continues to build solid intellectual property protection that reinforces our business opportunities as we attempt to rapidly move forward into the commercialization stage of the tissue welding technology."

Having recently completed design of the first specific procedure device for duct and vessel sealing, LTC has identified thus far 13 specific procedure devices from the list of over 80 types of procedures performed by the technology's universal device used in Ukraine. LTC expects multiple licensing and marketing opportunities for the technology based upon each specific procedure device. LTC has begun the development of the second prototype specific procedure device for end-to-end, end-to-side and side-to-side anastomosis (reconnection) of intestines which it expects to be completed in about four months.

LTC expects to complete a U.S. and European regulatory device for duct and vessel sealing meeting FDA and European CE Mark standards, respectively, and file for approval of the device with the two regulatory entities early next year.

About Human Tissue Welding/Bonding Technology

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 6,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues. The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to http://www.ctum.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CSMG Technologies, Inc. - 500 No. Shoreline # 701 no. - Corpus Christi, TX 78471